Several clinical trials using inhibitors of HGF/Met, MAP-kinase, m-TOR pathways and Wnt-signaling or small-molecule beta catenin inhibitors are ongoing in metastatic colorectal cancer, and optimal patient selection for effective use of these antagonists remains to be established [45]. Here, HGF is linked to metastatic colorectal cancer.